CitraFlow™ 4% (trisodium-citrate) La manera segura y fácil de que se bloquee cada catéter

CitraFlow™ 4% 2.5ml jeringa precargada

1. Anticoagulante
2. Anti-biopelícula
3. Seguro / No tiene efectos secundarios 
4. Ahorro de tiempo
5. Evita las hemorragias asociadas con la heparina
6. Frecuencia de uso y coste menor en el uso de APT (Activadores Plasminógenos de Tejidos)
7. Seguro para la trombocitopenia inducida por heparina (pacientes afectados)

Box contains 150 syringes

CitraFlow™ (Trisodium citrate 4%)

REFERENCES:
1. Bayes B et al (1999) Sodium Citrate for filling hemodiaysis catheters. Nephrol Dial Transplant 14, 2532-2533
2. Buturovic J et al (1998) Filling hemodialysis catheters in the interdialytic period. Artif Organs 22, 945-947
3. Grudzinski L et al (2007) Sodium citrate 4% locking solution for central venous dialysis catheters-an effective, more cost-efficient alternative to heparin.
Nephrol Dial Transplant 22: 471-476
4. Hendrickx L et al (2001) A comparative study on the use of low concentrate citrate lock. Int J Artif Organs 24, 208-211
5. Lok CE et al (2005) Trisodium citrate 4%-an alternatieve to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 22, 477-483
6. Meeus G et al (2005) A prospective, randomized, double-blind crossover study on the use of 5% citrate-lock vs 10% citrate-lock. Blood Purif 23, 101-105
7. Michaud D et al (2001) Four percent trisodium citrate as an effective anticoagulant. Am J Crit Care 10, 351-354
8. Moran JE and Ash SE (2008) Locking Solutions for Hemodialysis Catheters; Heparin and Citrate. A Position Paper by ASDIN. Seminars in Dialysis 21,1-3
9. Dreyer G et al (2008) Heparin leak from a hemodialysis catheter causing major bleeding, ultimately leading to transplant rejection and death.
HDI Volume 12, Number 4, October 2008, pp. 431-433(3)

Also Available in 5 ml vials: Citra-LockTM 4%

Citra-Lock™ 4%
Citra-Lock™ 30%
Citra-Lock™ 46,7%

Citra-Lock™ and Citra-Flow™ are registered as a medical device (Class IIb)